ReP USP - Resultado da busca

Artigo de periodico
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia (2020)
Santos Filho, Raul Dias dos ; Stein, Evan A.; Hovingh, G. Kees; Blom, Dirk J; Soran, Handrean; Watts, Gerald F; Lopez, J. Antonio G; Bray, Sarah; Kurtz, Christopher E; Hamer, Andrew W
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, ANTICORPOS MONOCLONAIS, ENZIMAS PROTEOLÍTICAS, ANTIMETABÓLITOS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS FILHO, Raul Dias dos et al. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 75, n. 6, p. 565-574, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.12.020. Acesso em: 27 abr. 2026.
APA
Santos Filho, R. D. dos, Stein, E. A., Hovingh, G. K., Blom, D. J., Soran, H., Watts, G. F., et al. (2020). Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, 75( 6), 565-574. doi:10.1016/j.jacc.2019.12.020
NLM
Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2026 abr. 27 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
Vancouver
Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2026 abr. 27 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
Artigo de periodico
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (2018)
Giugliano, Robert P.; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIUGLIANO, Robert P. e NICOLAU, Jose Carlos. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, v. 137, n. 15, p. 1571-0, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.117.030950. Acesso em: 27 abr. 2026.
APA
Giugliano, R. P., & Nicolau, J. C. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137( 15), 1571-0. doi:10.1161/CIRCULATIONAHA.117.030950
NLM
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2026 abr. 27 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Vancouver
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2026 abr. 27 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Artigo de periodico
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial (2018)
Berwanger, Otavio; Nicolau, José Carlos
Source: American heart journal. Unidade: FM
Subjects: FÁRMACOS (SISTEMA CARDIOVASCULAR), INFARTO DO MIOCÁRDIO, SÍNDROME CORONARIANA AGUDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERWANGER, Otavio e NICOLAU, José Carlos. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial. American heart journal, v. 202, p. 89-96, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2018.02.017. Acesso em: 27 abr. 2026.
APA
Berwanger, O., & Nicolau, J. C. (2018). Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial. American heart journal, 202, 89-96. doi:10.1016/j.ahj.2018.02.017
NLM
Berwanger O, Nicolau JC. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial [Internet]. American heart journal. 2018 ; 202 89-96.[citado 2026 abr. 27 ] Available from: https://doi.org/10.1016/j.ahj.2018.02.017
Vancouver
Berwanger O, Nicolau JC. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: rationale and design of the ticagrelor in patients with ST-elevation myocardial infarction treated with thrombolysis (TREAT) trial [Internet]. American heart journal. 2018 ; 202 89-96.[citado 2026 abr. 27 ] Available from: https://doi.org/10.1016/j.ahj.2018.02.017
Artigo de periodico
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD (2017)
Charytan, David M.; Burdmann, Emmanuel de Almeida
Source: American journal of kidney diseases. Unidade: FM
Subjects: FALÊNCIA RENAL CRÔNICA, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS, INFARTO DO MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHARYTAN, David M. e BURDMANN, Emmanuel de Almeida. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American journal of kidney diseases, v. 70, n. 4, p. 522-531, 2017Tradução . . Disponível em: http://observatorio.fm.usp.br/handle/OPI/21785. Acesso em: 27 abr. 2026.
APA
Charytan, D. M., & Burdmann, E. de A. (2017). ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American journal of kidney diseases, 70( 4), 522-531. doi:10.1053/j.ajkd.2017.04.018
NLM
Charytan DM, Burdmann E de A. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD [Internet]. American journal of kidney diseases. 2017 ; 70( 4): 522-531.[citado 2026 abr. 27 ] Available from: http://observatorio.fm.usp.br/handle/OPI/21785
Vancouver
Charytan DM, Burdmann E de A. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD [Internet]. American journal of kidney diseases. 2017 ; 70( 4): 522-531.[citado 2026 abr. 27 ] Available from: http://observatorio.fm.usp.br/handle/OPI/21785

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies